-
公开(公告)号:US07632486B1
公开(公告)日:2009-12-15
申请号:US09763370
申请日:1999-08-20
申请人: Etsuro Ogata , Mitsuru Koizumi , Shunji Takahashi
发明人: Etsuro Ogata , Mitsuru Koizumi , Shunji Takahashi
CPC分类号: G01N33/574 , G01N33/57488 , G01N33/6887 , G01N2333/47 , Y10T436/10 , Y10T436/25
摘要: Bone metastasis and the efficacy of drugs in the treatment of malignant tumors such as breast cancer, prostatic cancer and lung cancer that cause the bone metastasis are diagnosed using a marker that reflects the activity of osteoblasts and a marker that reflects the action of osteoclasts.
摘要翻译: 使用反映成骨细胞的活性的标记物和反映破骨细胞作用的标记物诊断骨转移和药物治疗引起骨转移的乳腺癌,前列腺癌和肺癌等恶性肿瘤的功效。
-
公开(公告)号:US06566351B1
公开(公告)日:2003-05-20
申请号:US09091185
申请日:1998-06-10
申请人: Etsuro Ogata , Kyoji Ikeda , Koichi Endo
发明人: Etsuro Ogata , Kyoji Ikeda , Koichi Endo
IPC分类号: A61K3159
CPC分类号: A61K31/593 , A61K31/59
摘要: Pharmaceutical agents containing a compound of the general formula (I): wherein R1 represents —O—R2, —S—R2, —CH2—R2 or —CH═R2 where R2 represents a C1-C10 chain hydrocarbon group which may be substituted by one or more hydroxyl groups, and R3 represents a hydrogen atom or a hydroxyl group are useful as malignant tumor metastasis inhibitors without any especially strong side effects.
摘要翻译: 含有通式(I)化合物的药剂:其中R1表示-O-R2,-S-R2,-CH2-R2或-CH = R2,其中R2表示C1-C10链烃基,其可以被 一个或多个羟基,R 3表示氢原子或羟基,可用作恶性肿瘤转移抑制剂而没有任何特别强的副作用。
-
公开(公告)号:US5662604A
公开(公告)日:1997-09-02
申请号:US495635
申请日:1995-09-19
申请人: Etsuro Ogata , Kiyoshi Kurokawa , Shunya Uchida , Akiko Kishida
发明人: Etsuro Ogata , Kiyoshi Kurokawa , Shunya Uchida , Akiko Kishida
CPC分类号: C12Q1/34 , G01N2333/924
摘要: A screening method for detecting renal lesions in diabetic patients not yet exhibiting symptoms of nephropathy, comprising administering a predetermined dose of parathyroid hormone, analogue thereof or derivative thereof to the patients with an albumin excretion rate (AER) of microalbumin being below 15 .mu.g/min., measuring urinary excreted N-acetyl-.beta.-D-glucosaminidase (NAG) and urinary creatinine in urinary samples taken 60.+-.10 minutes before and after administration of PTH, and monitoring the increased ratio of urinary excreted NAG (U/g Cr) in post-administration of PTH to the urinary excreted NAG (U/g Cr) in pre-administration of PTH for a value less than 2.3. The screening method provides the possibility of detecting renal lesions without clinical signs of diabetic nephropathy, using a preparation essentially consisting of active ingredient of PTH.
摘要翻译: PCT No.PCT / JP93 / 00178 Sec。 371 1995年9月19日第 102(e)1995年9月19日PCT 1993年2月12日提交PCT未检测出肾病症状的糖尿病患者的肾脏损害检测方法,其特征在于,向患者施用预定量的甲状旁腺激素,其类似物或其衍生物 微量白蛋白的白蛋白排泄率(AER)低于15μg/ min,在尿样中测量尿排泄的N-乙酰基-β-D-氨基葡萄糖苷酶(NAG)和尿肌酐,在前后60±10分钟内摄取 给予PTH,并监测在PTH给药前尿中排泄的NAG(U / g Cr)与PTH前期尿液排泄的NAG(U / g Cr)的比例增加,小于2.3。 筛选方法提供了检测肾病变的可能性,没有糖尿病肾病的临床体征,使用基本上由PTH活性成分组成的制剂。
-
公开(公告)号:US07655227B1
公开(公告)日:2010-02-02
申请号:US10019501
申请日:2000-07-03
申请人: Etsuro Ogata , Etsuro Onuma , Toshiaki Tsunenari , Hidemi Saito , Yumiko Azuma
发明人: Etsuro Ogata , Etsuro Onuma , Toshiaki Tsunenari , Hidemi Saito , Yumiko Azuma
IPC分类号: A61K39/395 , A61K38/22 , C07K16/26 , C12P21/08
CPC分类号: C07K16/26
摘要: The present invention provides an agent for ameliorating low vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof; and an agent for ameliorating a symptom caused by a decrease in vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.
摘要翻译: 本发明提供一种用于改善低加压素水平的药剂,其包含作为活性成分的能够抑制甲状旁腺激素相关肽(PTHrP)与其受体之间的结合的物质; 以及用于改善由加压素水平降低引起的症状的药剂,其包含作为活性成分的能够抑制甲状旁腺激素相关肽(PTHrP)与其受体之间的结合的物质。
-
公开(公告)号:US06869940B2
公开(公告)日:2005-03-22
申请号:US10135846
申请日:2002-05-01
申请人: Etsuro Ogata , Kyoji Ikeda , Koichi Endo
发明人: Etsuro Ogata , Kyoji Ikeda , Koichi Endo
IPC分类号: A61K31/59 , A61K31/593
CPC分类号: A61K31/59 , A61K31/593
摘要: A method for inhibiting bone metastasis of a malignant tumor in a patient who has a cancer excluding breast cancer comprises administering to said patient an effective amount of a compound of the formula (III): wherein R2 represents a C1-C10 alkyl group substituted by one or more hydroxyl groups is provided.
摘要翻译: 一种抑制患有除了乳腺癌以外的癌症的患者中的恶性肿瘤的骨转移的方法包括向所述患者施用有效量的式(III)化合物:其中R 2表示被一个 或更多的羟基。
-
公开(公告)号:US5240911A
公开(公告)日:1993-08-31
申请号:US410402
申请日:1989-09-21
申请人: Yasuo Totsuka , Itaru Kojima , Etsuro Ogata , Makoto Shiozaki , Shigeru Shioya , Hiroshiro Shibai , Yuzuru Eto
发明人: Yasuo Totsuka , Itaru Kojima , Etsuro Ogata , Makoto Shiozaki , Shigeru Shioya , Hiroshiro Shibai , Yuzuru Eto
IPC分类号: C12P21/02 , A61K38/00 , A61K38/22 , A61P3/08 , A61P3/10 , C07K1/20 , C07K14/52 , C07K14/575 , C12N15/09 , C12R1/91
CPC分类号: A61K38/22
摘要: Pharmaceutical compositions containing the polypeptides BUF-3, BUF-4 and BUF-5 have hypoglycemic activity. BUF-3 is a homodimer of monomer A shown in FIG. 1. The monomer has a molecular weight of 16.+-.1 kd. BUF-4 is a heterodimer of monomer A and monomer B (FIG. 2). These products can be produced by cell culture of malignant leukemia cells or by recombinant DNA engineering.
摘要翻译: 含有多肽BUF-3,BUF-4和BUF-5的药物组合物具有降血糖活性。 BUF-3是图1所示的单体A的同二聚体。 单体的分子量为16 +/- 1kd。 BUF-4是单体A和单体B的异二聚体(图2)。 这些产品可以通过恶性白血病细胞的细胞培养或通过重组DNA工程产生。
-
-
-
-
-